David Rinaldi
Overview
Explore the profile of David Rinaldi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
208
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fernandez N, Mani R, Rinaldi D, Kadau D, Mosquet M, Lombois-Burger H, et al.
Phys Rev Lett
. 2014 Aug;
111(10):108301.
PMID: 25166716
We propose a simple model, supported by contact-dynamics simulations as well as rheology and friction measurements, that links the transition from continuous to discontinuous shear thickening in dense granular pastes...
2.
Ramalingam S, Perry M, La Rocca R, Rinaldi D, Gable P, Tester W, et al.
Cancer
. 2008 May;
113(3):542-6.
PMID: 18512224
Background: The purpose of this study was to compare the outcomes between elderly (aged > or = 70 years) patients treated with paclitaxel on a weekly basis and with carboplatin...
3.
Belani C, Ramalingam S, Perry M, LaRocca R, Rinaldi D, Gable P, et al.
J Clin Oncol
. 2008 Jan;
26(3):468-73.
PMID: 18202422
Purpose: To compare the efficacy and safety of weekly paclitaxel in combination with carboplatin administered every 4 weeks to the standard regimen of paclitaxel and carboplatin administered every 3 weeks...
4.
Ramalingam S, Barstis J, Perry M, La Rocca R, Nattam S, Rinaldi D, et al.
J Thorac Oncol
. 2007 Apr;
1(3):240-4.
PMID: 17409863
Background: Administration of paclitaxel on a weekly schedule in combination with carboplatin is associated with a lower incidence of neuropathy and myelosuppression. The authors conducted subgroup analysis of their randomized...
5.
Hainsworth J, Yardley D, Spigel D, Meluch A, Rinaldi D, Schnell F, et al.
Cancer Invest
. 2006 Aug;
24(5):469-73.
PMID: 16939953
Background: Taxanes and anthracyclines are the two most active classes of cytotoxic agents in the treatment of patients with metastatic breast cancer. Epirubicin, a doxorubicin analog, has shown modest toxicity...
6.
Vaughn D, Brown Jr A, Harker W, Huh S, Miller L, Rinaldi D, et al.
Cancer
. 2004 Feb;
100(4):746-50.
PMID: 14770430
Background: The current study determined the efficacy and toxicity of weekly paclitaxel in combination with estramustine phosphate (EMP) in patients with androgen-independent prostate carcinoma (AIPC). Methods: Patients with progressive AIPC...
7.
Belani C, Barstis J, Perry M, La Rocca R, Nattam S, Rinaldi D, et al.
J Clin Oncol
. 2003 Jul;
21(15):2933-9.
PMID: 12885812
Purpose: To explore the efficacy and safety of three regimens of weekly paclitaxel plus carboplatin as initial therapy and the feasibility of subsequent maintenance therapy versus observation in patients with...
8.
Fuchs C, Moore M, Harker G, Villa L, Rinaldi D, Hecht J
J Clin Oncol
. 2003 Mar;
21(5):807-14.
PMID: 12610178
Purpose: Randomized trials in fluorouracil (FU)-refractory colorectal cancer demonstrate significant survival advantages for patients receiving irinotecan. We prospectively compared the efficacy and tolerability of two irinotecan regimens (once a week...